Projektbidrag och kliniska forskarmånader 2022-2024
Utlysningsperioden för CIMEDs projektbidrag och kliniska forskarmånader för 2022-2024 är avslutad och beslut om fördelning av medel har fattats av CIMEDs styrelse enligt rekommendation från granskningsgrupperna.
Följande personer har tilldelats CIMED projektbidrag (P) och/eller kliniska forskarmånader (F):
Juniornivå
Carl Jorns – The landscape and role of tissue-resident lymphocytes in human organ donors and liver transplantation. (P+F)
Cecilia Morgantini – Characterize the immunological response of diabetic patients with chronic foot ulcers. (P)
Daniel Andersson – Effekter av könskonträr hormonbehandling på muskler, fettväv och metabola riskfaktorer samt metabola långtidseffekter av könsskillnader i fettvävens förmåga att frisätta fettsyror. (F)
David Moulaee Conradsson – How can promotion of physical activity after stroke or transient ischemic attack work remotely? Evaluation of an innovative telerehabilitation program to improve cardiovascular health. (P)
Dhifaf Sarhan – Targeting FPR2 as a novel approach for immunotherapy in pancreatic cancer female patients – Studies of sexual immune dimorphism in the tumor microenvironment. (P)
Erik Forsell – ”Utveckling och utvärdering av två behandlingsprogram för överdriven oro i reguljär psykiatrisk vård: Internetbaserad behandling för vuxna med generaliserat ångestsyndrom (GAD)”. (P)
Hannes Hagström – Förbättrad diagnostik och prognostisering vid fettlever. (F)
Hannes Olauson – Targeting ischemia-reperfusion injury in kidney transplantation to improve graft function and survival. (P)
Hong Xu – Dementia, kidney disease and COVID-19. (P)
Joel Nordin – Engineered Cells for targeted pancreas cancer therapy by therapeutic Extracellular Vesicle secretion in the diseased microenvironment. (P)
John Wallert – PRiSMED: Prediction of health and socioeconomic outcomes for patients with common psychiatric disorders. (P)
Lotta Herling – Fosters hjärtfunktion och intrauterin tillväxthämning – förbättrade metoder för att bedöma långtidsrisk för kardiovaskulär sjukdom. (F)
Magnus Tobiasson – Minimal residual disease (MRD)-targeted treatment to improve outcome of allogeneic stem cell transplantation (HCT) for patients with myelodysplastic syndrome (MDS). (F)
Marco Gerling – A clinical tool for improved pancreatic cancer therapy and a molecular map of tumor invasion. (P)
Marie Evans – Advanced chronic kidney disease – new implications of uremic toxins on cardiovascular disease, uremic symptoms and quality of life. (F)
Martin Cornillet – Systems biology of liver regeneration to improve tumor resection: From basics to clinics. (P)
Mattias Carlsten – Improving outcome and quality of life for post-transplant leukemia relapse patients by directing donor lymphocytes to the bone marrow and thereby avoid GvHD – Clinical implementation of a novel 3D imaging method. (P)
Miroslav Vujasinovic – Metabolic consequences of chronic pancreatitis. (F)
Ola Blennow – IMST-studien: Hur korrelerar immunstatus hos IMmunsupprimerade patienter med svårighetsgrad och duration av SMittsamhet vid covid-19 infektion? (P+F)
Pernilla Danielsson Liljeqvist – En randomiserad kontrollerad multicenterstudie för utvärdering av ett digitalt stödsystem i barnfetmabehandling – EurEvira. (P)
Roland Fiskesund – Utveckling och utvärdering av neutrofiltranfusion för behandling av antibiotikaresistenta infektioner hos neutropena patienter. (F)
Sandra Tamm – Akut psykologisk sömnstabilisering för patienter med inläggningskrävande depression – en randomiserad kontrollerad studie.(P+F)
Soham Gupta – Identifying the cause of death in COVID-19 and post-COVID syndrome using molecular autopsy and multi-omics approach. (P)
Urban Ekman – A collected clinical approach aiming at improved diagnostic accuracy and development of novel effective psychosocial interventions in patients with early-phase cognitive impairments. (P)
Vanessa Lundin – Modelling Bone Marrow Disease in-a-dish: Studies of Molecular Mechanisms underlying Myeloid Malignancies. (P)
Volen Ivanov – A concentrated exposure-based treatment vs gold-standard cognitive behavior therapy for obsessive-compulsive disorder: a single blind randomized controlled trial. (P+F)
Åsa Bonnard – Kolesteatom i Sverige – en Nationell studie med Lokal fördjupning. (F)
Seniornivå
Anna Rising – A new injectable material for bone regeneration and novel strategies for fracture repair. (P)
Anna-Karin Welmer – Preventing functional decline in acutely hospitalized older patients – effect of a simple exercise program versus individualized multicomponent training (PREV FUNC study). (P)
Björn Fischler – Flera nyanser av gult. Patogenes, förlopp och behandling av spädbarn med olika former av gallstassjukdom. (F)
Bo Angelin – ”Finding novel causes of familial hypercholesterolemia in Sweden – Nya mekanismer för familjär hyperkolesterolemi i Sverige”. (P)
Cecilia Götherström – BOOSTB4: Boost Brittle Bones Before Birth – a clinical trial to treat severe Osteogenesis Imperfecta before and after birth. (P)
Edvard Smith – BTK inhibitors in leukaemia and inflammatory disease. (P)
Erik Eliasson – Precision Medicine by personalized dosing of capecitabine and tamoxifen in breast cancer – next generation sequencing, phenotype markers and modeling of patient-unique genetic variants. (F)
Fredrik Lanner – Embryonic stem cell based treatment of retinal degenerative disease. (P)
Ganesh Acharya – A translational study to improve fertility outcome after cancer treatment in young women: The development of organoid systems to support follicle development in vitro and endometrial recovery. (P)
Greg Nowak – Intrahepatic microdialysis in continuous assessment of liver graft during static or dynamic preservation and early after transplantation – clinical study. (F)
Hareth Nahi – Low dose venetoclax as a single agent treatment of plasma cell malignancies harbouring t(11;14). (P)
Ingrid Dahlman – Elucidating the interplay between circadian rhythm and physical exercise on metabolism in patients with typ 1 diabetes and overweight. (P)
Ioannis Rouvelas – Novel modalities in the management of advanced gastric cancer-the role of minimally invasive surgery and the Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). (F)
Jonas Sunden-Cullberg – Sepsis på akutmottagning och intensivvårdsavdelning – kan ett sepsislarm identifiera rätt patienter, ge mer jämlik behandling och minska dödlighet? (F)
Katarina Le Blanc – ”An open Phase I/II study in patients with dysphonia and vocal fold scarring to evaluate safety, tolerability and vocal function after surgery with local administration of autologous mesenchymal stromal cells”. (P)
Lars-Olof Wahlund – Alkohol och demenssjukdom -Finns det något samband? (P)
Margaret Sällberg Chen – Salivary biofluid in Covid-19 immunity surveys: Infection and vaccination. (P)
Michael Uhlin – Development, utilization and evaluation of novel immune therapies in allogenic hematopoietic stem cell transplantation. (P)
Mikael Sundin – Rätt metod vid rätt tillfälle – från blodstatus till helgenomsekvensering i barnhematologisk diagnostik. (F)
Niklas Björkström – Utilizing clinical intervention in severe viral infections to study pathogenesis and treatment mechanisms. (P)
Olav Rooyackers – Personalizing protein nutrition for the critically ill. (P)
Piotr Nowak – The impact of microbiome and HIV-reservoir on immunological response to vaccination against SARS-CoV-2 in patients with HIV. (F)
Qiang Pan-Hammarström – Clinical and genetic studies on malignant B cell lymphomas –basis for development of better prognostic models and novel therapies. (P)
Rula Zain – Unik behandling av trinukleotid-repeat sjukdomar. (P)
Soo Aleman – Immunologiskt svar efter Covid-19 mRNA vaccination av patienter med nedsatt immunförsvar. (P)
Staffan Wahlin – Leversjukdom och levercancer vid akut intermittent porfyri. (F)
Stellan Hertegård – An open Phase I/II study in patients with dysphonia and vocal fold scarring to evaluate safety, tolerability and vocal function after surgery and local administration of autologous mesenchymal stromal cell product. (F)
Thomas Gustafsson – Funktionsbegränsning hos långtids-covidpatienter samt effekter av rehabilitering med fokus på genomförbarhet och långsiktighet. (P)
Uwe Tietge – Characterization of the clinical value of the anti-inflammation function of high density lipoproteins (HDL) for cardiovascular risk prediction. (P)
Utlysningstext och beredningsordning
CIMED projektbidrag och kliniska forskarmånader 2022-2024
Uppdaterad av:
Amanda Klein 2022-05-02